David N. Deaton
GlaxoSmithKline (United States) · 62 works · 1,458 citations · h-index 25
Top works
- Matrix Metalloproteinase Inhibitors Containing a [(Carboxyalkyl)amino]zinc Ligand: Modification of the P1 and P2' Residues
- Stereocontrolled one-pot conversions of α-alkoxy esters to syn- and anti-1,2-diol derivatives
- Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
- Synthesis and Evaluation of Potent and Selective β3 Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres
- Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors
- Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
- Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis
- Novel and potent cyclic cyanamide-based cathepsin K inhibitors
- Cathepsin K Inhibitors: Their Potential as Anti-Osteoporosis Agents
- Exploration of the P1 SAR of aldehyde cathepsin K inhibitors
- Exploration of the P2–P3 SAR of aldehyde cathepsin K inhibitors
- Potent and selective P2–P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1′, P1, and/or P3 substitutions
- Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K
- アルデヒド系カテプシンK阻害剤のP 1 部位SAR探究
- Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064
- Design of small molecule ketoamide-based inhibitors of cathepsin K
- Synthesis of (+)-dihydrocompactin and (+)-compactin via vinylsilane terminated cationic cyclization
- P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K
- FXR agonist activity of conformationally constrained analogs of GW 4064
- Design of Cathepsin K Inhibitors for Osteoporosis